MPS II
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| MPS II Immunophenotyping (NCT04976231) | Duke University | 2022-04-01 |
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) (NCT04532047) | University of California, San Francisco | 2021-07-01 |
| An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) (NCT07344376) | GC Biopharma Corp | 2018-05-23 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II (NCT03041324) | Sangamo Therapeutics | 2017-05-11 |
| Longitudinal Study of Neurodegenerative Disorders (NCT03333200) | University of Pittsburgh | 2012-01-11 |
| Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy (NCT00607386) | Shire | 2007-12-31 |
Track MPS II automatically
Every clearance here is in the API, with alerts when new ones post.